Study Agreement between Weill Cornell and COPD Foundation - SPRIOMICS

ACRC New York Consortium

Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients

Center for Improving Palliative Care for Vulnerable Adults with MCC (CIPC)

SPIROMICS II: Biological underpinnings of COPD heterogeneity and progression

Epigenetic alterations and phenotypes in innate immune cells and their progenitors in PASC

Beta-Blockers for the Prevention of Acute Exacerbations of COPD

ALA- Airways Clinical Research Centers (ACRC) network: Losartan Effects on Emphysema Progression Trial (LEEP) Trial

In Vivo Biomarker that Identifies Waterpipe Smoking-Related Lung Health

Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)-RETHINC

(RETHINC) - Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)

ALA- Airways Clinical Research Centers (ACRC) network - COCO

HIV Reprogrammed Airway Basal Cells Acquire a “Tissue Destructive” Phenotype

Assessment and Gene Repair of Human CF Airway Basal Stem/Progenitor Cells

HIV+ Alveolar Macrophage Oxidant-Mediated Apoptosis of Pulmonary Endothelium

Parametric Response Mapping in COPD

Biology of the Oral Epithelium of E-Cigarette Smokers

HIV-Related Accelerated Aging of the Airway Epithelium

Doxycycline for COPD in HIV-Infected Patients

Subpopulation and Intermediate Outcome Measure in COPD Study SPIROMICS: Clinical Center

Gene Therapy for Batten Disease Using AAVrh.10 Expressing Human CLN2 cDNA

Idiopathic Pulmonary Fibrosis Clinical Research Network

Role of Alveolar Macrophages in the Accelerated Emphysema of HIV-1 Positive

Alveolar Macrophage Host Defenses

Vascular endothelial growth factor induced lung edema

Is there a need for gender specific adapted therapy in the treatment of COPD?

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

A 52-week, Randomized, Double-blind, Double-dummy, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg), Parallel Group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis.

The Development and Pilot Testing of a Brief Shared Decision-Making Intervention to Improve Palliative Care Outcomes for Adults With Advanced Lung Disease

TOLLIP single nucleotide polymorphism and treatment effect in IPF

Mitochondrial dysfunction as a hallmark of interstitial lung disease

SPIROMICS Study of Early COPD Progression (SOURCE)

A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Garadacimab in Subjects With Idiopathic Pulmonary Fibrosis

An Observational Study of Beta-Blocker Use in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Acute Myocardial Infarction

A multi-center, real-world exploratory cohort study to evaluate cough frequency, severity, and impact on quality of life in patients with non-idiopathic pulmonary fibrosis interstitial lung disease

A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD

TRK-250 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Inhaled Dose, Safety, Tolerability, and Pharmacokinetic Study of TRK-250 in Subjects With Idiopathic Pulmonary Fibrosis

An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Post COVID-19 Hypoxemic Respiratory Failure Residual Pathophysiologic Outcomes

Individual Patient Expanded Access of REGEN-COV Investigational New Drug Application (sIND) #157001

Individual Patient Expanded Access Investigational New Drug Application (IND), Clofazimine. sIND#147574

Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial

Individual Patient Expanded Access Investigational New Drug Application (IND), Clofazimine. sIND # 146693

Study of Pulmonary Rehabilitation In Nintedanib Treated Patients With IPF: Improvements in Activity, Exercise Endurance Time, and QoL